PANDEMIC RESPONSE
industry, to partner with innovative and nontraditional companies. As a result, JPEO-CBRND was able to draw on years of in-depth experience with other- transaction authority negotiations and awards in order to accelerate contract actions for COVID-19 efforts without compromising integrity or accountability.
"Te DOD has specific skills, authori- ties and experience to work these types of quick-turn actions,” said George Sfakianoudis, JPEO-CBRND chief finan- cial officer. “In order to apply the DOD's abilities to support Operation Warp Speed, DHA and others, a thorough review of the contractual and financial systems and processes was done before we executed the first penny against these efforts."
PRECISE PREPARATION
EXISTING CAPABILITIES One of JPEO-CBRND’s primary custom- ers is the National Guard Bureau. As the nation’s first line of defense, the National Guard’s weapons of mass destruction civil support teams assist state and local authorities responding to domestic CBRN incidents. Te teams are in every state, on standby 24/7 throughout the year. As COVID-19 grew into a global pandemic and the number of infected people increased in the United States, those teams were on the front lines, providing testing capabilities to some of the nation’s hard- est-hit areas.
Much-needed personal protective equip- ment and diagnostic testing became priorities
for first responders
Erica Borgers-Klonkowski, left, Alice Young, center, and Brant Lagoon prepare conical tubes for testing of the Joint Biological Aircraft Decontamination System Lite on a C-17A Globemaster III. The tubes contained Phi6, a biosafety level 1 bacteriophage. (U.S. Air Force photo by Roland Balik, 436th Airlift Wing Public Affairs)
in the
hardest-hit areas. JPEO-CBRND worked with the Defense Health Agency to expe- dite the procurement of masks, face shields and gowns, and accelerate the fielding of COVID-19 diagnostic systems. In the 2020 fiscal year, JPEO-CBRND deliv- ered more than 58 million items and has procured more than 1 billion items in total. JPEO-CBRND accelerated fielding
of DOD’s Next Generation Diagnos- tic System, known commercially as the BioFire FilmArray, to the joint force and the National Guard Bureau. Because of the need to expand testing quickly, and the understanding that no single system or company could meet the overwhelming demand, JPEO-CBRND also leveraged the Medical CBRN Defense Consortium Other Transition Authority to work with Cepheid Inc. to develop a testing platform that could provide clinical diagnostic test results within 45 minutes, compared with several hours.
Te systems that were either put into place, or were already being implemented at JPEO-CBRND to enable rapid response to CBRN threats, were used heavily to support the government’s COVID- 19 response. Tese included antibody production, DNA plasmid support and
development, access to rapidly discovered monoclonal antibody candidates, and assessment of whether monoclonal anti- body candidates were stable and able to be manufactured.
"We leveraged our existing relationships and formed new partnerships, which are critical to our ability to meet our day- to-day mission, to move our COVID-19 support efforts forward as fast as possible," said Chuck Nuce, JPEO-CBRND chief of operations and international.
Te largest of these existing relationships and partnerships is DOD Advanced Development and Manufacturing, a contractor-owned, contractor-operated facility located in Alachua, Florida, designed to develop and manufacture medical countermeasures for the war- fighter. The state-of-the-art equipment
https://asc.ar my.mil 19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176
